Small Bowel and Colorectal Carcinoids

Raphael M. Byrne, Rodney Pommier

    Research output: Contribution to journalArticle

    Abstract

    Neuroendocrine tumors, or carcinoid tumors, of both the midgut and hindgut are quite rare, but their incidence is increasing. Surgery is the treatment of choice in patients who can tolerate an operation and have operable disease. Options for the treatment of metastatic disease include cytoreductive surgery, somatostatin analogues, interferon α, local liver therapies (hepatic arterial embolization, ablation), chemotherapy, Peptide-Receptor Radionucleotide Radiotherapy, angiogenesis inhibitors, and mammalian target of rapamycin inhibitors.

    Original languageEnglish (US)
    Pages (from-to)301-308
    Number of pages8
    JournalClinics in Colon and Rectal Surgery
    Volume31
    Issue number5
    DOIs
    StatePublished - Jan 1 2018

    Fingerprint

    Carcinoid Tumor
    Angiogenesis Inhibitors
    Peptide Receptors
    Neuroendocrine Tumors
    Liver
    Sirolimus
    Somatostatin
    Interferons
    Radiotherapy
    Therapeutics
    Drug Therapy
    Incidence

    Keywords

    • appendiceal NET
    • carcinoid tumors
    • colorectal NET
    • jejunoileal NET
    • neuroendocrine tumors

    ASJC Scopus subject areas

    • Surgery
    • Gastroenterology

    Cite this

    Small Bowel and Colorectal Carcinoids. / Byrne, Raphael M.; Pommier, Rodney.

    In: Clinics in Colon and Rectal Surgery, Vol. 31, No. 5, 01.01.2018, p. 301-308.

    Research output: Contribution to journalArticle

    Byrne, Raphael M. ; Pommier, Rodney. / Small Bowel and Colorectal Carcinoids. In: Clinics in Colon and Rectal Surgery. 2018 ; Vol. 31, No. 5. pp. 301-308.
    @article{f71b368025324052b7feb55f43f17ac3,
    title = "Small Bowel and Colorectal Carcinoids",
    abstract = "Neuroendocrine tumors, or carcinoid tumors, of both the midgut and hindgut are quite rare, but their incidence is increasing. Surgery is the treatment of choice in patients who can tolerate an operation and have operable disease. Options for the treatment of metastatic disease include cytoreductive surgery, somatostatin analogues, interferon α, local liver therapies (hepatic arterial embolization, ablation), chemotherapy, Peptide-Receptor Radionucleotide Radiotherapy, angiogenesis inhibitors, and mammalian target of rapamycin inhibitors.",
    keywords = "appendiceal NET, carcinoid tumors, colorectal NET, jejunoileal NET, neuroendocrine tumors",
    author = "Byrne, {Raphael M.} and Rodney Pommier",
    year = "2018",
    month = "1",
    day = "1",
    doi = "10.1055/s-0038-1642054",
    language = "English (US)",
    volume = "31",
    pages = "301--308",
    journal = "Clinics in Colon and Rectal Surgery",
    issn = "1531-0043",
    publisher = "Thieme Medical Publishers",
    number = "5",

    }

    TY - JOUR

    T1 - Small Bowel and Colorectal Carcinoids

    AU - Byrne, Raphael M.

    AU - Pommier, Rodney

    PY - 2018/1/1

    Y1 - 2018/1/1

    N2 - Neuroendocrine tumors, or carcinoid tumors, of both the midgut and hindgut are quite rare, but their incidence is increasing. Surgery is the treatment of choice in patients who can tolerate an operation and have operable disease. Options for the treatment of metastatic disease include cytoreductive surgery, somatostatin analogues, interferon α, local liver therapies (hepatic arterial embolization, ablation), chemotherapy, Peptide-Receptor Radionucleotide Radiotherapy, angiogenesis inhibitors, and mammalian target of rapamycin inhibitors.

    AB - Neuroendocrine tumors, or carcinoid tumors, of both the midgut and hindgut are quite rare, but their incidence is increasing. Surgery is the treatment of choice in patients who can tolerate an operation and have operable disease. Options for the treatment of metastatic disease include cytoreductive surgery, somatostatin analogues, interferon α, local liver therapies (hepatic arterial embolization, ablation), chemotherapy, Peptide-Receptor Radionucleotide Radiotherapy, angiogenesis inhibitors, and mammalian target of rapamycin inhibitors.

    KW - appendiceal NET

    KW - carcinoid tumors

    KW - colorectal NET

    KW - jejunoileal NET

    KW - neuroendocrine tumors

    UR - http://www.scopus.com/inward/record.url?scp=85053104033&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85053104033&partnerID=8YFLogxK

    U2 - 10.1055/s-0038-1642054

    DO - 10.1055/s-0038-1642054

    M3 - Article

    VL - 31

    SP - 301

    EP - 308

    JO - Clinics in Colon and Rectal Surgery

    JF - Clinics in Colon and Rectal Surgery

    SN - 1531-0043

    IS - 5

    ER -